Free Trial
NASDAQ:ATHE

Alterity Therapeutics (ATHE) Stock Price, News & Analysis

Alterity Therapeutics logo
$4.25 +0.02 (+0.47%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$4.10 -0.15 (-3.62%)
As of 05/23/2025 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alterity Therapeutics Stock (NASDAQ:ATHE)

Key Stats

Today's Range
$4.10
$4.25
50-Day Range
$2.54
$4.80
52-Week Range
$1.00
$5.87
Volume
8,081 shs
Average Volume
143,766 shs
Market Capitalization
$37.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Moderate Buy

Company Overview

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

ATHE MarketRank™: 

Alterity Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 677th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Alterity Therapeutics has received no research coverage in the past 90 days.

  • Read more about Alterity Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.35% of the float of Alterity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alterity Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alterity Therapeutics has recently decreased by 11.80%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Alterity Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Alterity Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.35% of the float of Alterity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alterity Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alterity Therapeutics has recently decreased by 11.80%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Alterity Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Alterity Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.14% of the stock of Alterity Therapeutics is held by institutions.

  • Read more about Alterity Therapeutics' insider trading history.
Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATHE Stock News Headlines

Alterity Therapeutics highlighted at MSA Congress
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

ATHE Stock Analysis - Frequently Asked Questions

Alterity Therapeutics' stock was trading at $3.31 at the beginning of 2025. Since then, ATHE stock has increased by 28.4% and is now trading at $4.25.
View the best growth stocks for 2025 here
.

Alterity Therapeutics shares reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional investors of Alterity Therapeutics include HB Wealth Management LLC (0.42%).

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include NVIDIA (NVDA), GE Aerospace (GE), Broadcom (AVGO), Meta Platforms (META), Dorian LPG (LPG), CymaBay Therapeutics (CBAY) and

Company Calendar

Today
5/25/2025
Fiscal Year End
6/30/2025
Next Earnings (Estimated)
8/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATHE
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+182.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
4.09

Miscellaneous

Free Float
5,350,000
Market Cap
$37.68 million
Optionable
Not Optionable
Beta
0.65
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ATHE) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners